»Ê¼Ò»ªÈË

Translational Research refers to a particular type of research primarily aimed to improve human health. This means using basic knowledge in biology, technology, physics (..) for clinical uses.

Ìý

BASIC overview of the translational path

ACCELERATE Potential | UCL School of Life and Medical Sciences - UCL – University College London. This online course is an introduction to the Translational Research and the Translational Path. Self paced, for UCL staff/studentsÌýand externals.

The Academic Careers Office (ACO) at »Ê¼Ò»ªÈË is part of the Office of the Vice Provost for Health (OVPH). The OVPH's mission is to enhanceÌýexternal relationships in biomedicine with a range of medical research organisations, NHS included. The ACOÌýpromotes, supports and develops many aspects of academicÌýin health related disciplines across UCL. As UCL students and researchers at »Ê¼Ò»ªÈË Queen Square IoN, everyone is welcomed to use this resource.ÌýACCELERATE | UCL School of Life and Medical Sciences - UCL – University College London

ADVANCED overview of therapeutic development by modality: biologics, gene and cell therapy, devices and diagnostics, regenerative medicine, small molecule and repurposingo

Click on the modality you are interested to explore. Roadmaps:

-ÌýBiologics Translation Roadmap | UCL Therapeutic Innovation Networks - UCL – University College London
-ÌýCell & Gene Therapy Translation Roadmap | UCL Therapeutic Innovation Networks - UCL – University College London
-ÌýDevices Translation Roadmap | UCL Therapeutic Innovation Networks - UCL – University College London
-ÌýRegenerative Medicines Case Studies | UCL Therapeutic Innovation Networks - UCL – University College London
-ÌýSmall Molecules Translation Roadmap | UCL Therapeutic Innovation Networks - UCL – University College London Repurposing | UCL Therapeutic Innovation Networks - UCL – University College London

---

Landing page:ÌýUCL Therapeutic Innovations Networks (TINs) | UCL Therapeutic Innovation Networks - UCL – University College London.

---

TheseÌýresources areÌýoffered by the Therapeutic Innovations Networks (TINs @UCL). The TINsÌýis a specific framework embedded in the Translational Research Office (TRO)Ìýand partnered with NIHR Biomedical Research Centres (UCLH, Great Ormond Street Hospital, Moorfields eye hospital) for education, training and outreach of early career researchers.

The TRO's main purpose is to support translational research at »Ê¼Ò»ªÈË Translational Research Office | Translational Research Office (TRO) - UCL – University College London.

Webinars:ÌýTIN Webinar Recordings | UCL Therapeutic Innovation Networks - UCL – University College London

FOCUS on the development pathway and regulations of gene, cell and tissue therapy (ATMPs: advanced therapy medical products)

Advanced therapy medicinal products (ATMPs) are medicines for human use that areÌýeitherÌýa gene therapy medicinal product, a somatic cell therapy medicinal product, orÌýÌýa tissue engineered product. Here you can find informativeÌýmaterial from the UK and EU regulatory agency.

- MHRA (UK):Ìý
- EMA (EU):Ìý, and alsoÌý
More webinars and material on ATMPs from London Advanced Therapies in collaboration with NHS

- After the initial registration, search for key words such as 'cell/gene therapy'Ìý
- Ìýseries of talks, case studies and tool kit

Talk by Prof Mark Lowdell (UCL) on advancing ATMPs from academia to industryÌý

-ÌýÌý

Ìý

FOCUS on the development pathway and regulations of small molecules and devices

This presentationÌýwas made by Deloitte and published by gov.uk* (2016) as aÌýguide to navigating the innovation pathway in England. It includes development pathways for pharmaceuticals and medical technologies.ÌýÌý(*The document is pre-Brexit, therefore some links are not anymore up to date or available. Check with the TRO/TRM if you have specific questions). -Ìý.

Oxford also offers some interesting webinars freely available:

Small molecule:Ìý. The University of Oxford offers a series of videos to discuss the experience of innovators from pharma (Bayers, Astra Zeneca), but also regulators. Click here you hear about target validation, regulation, commercialisation and investment opportunities.Ìý
Devices:Ìý. The development of a device follows different regulations compared to a biologic.ÌýIt is also good practice to have an idea of the category to which the device belongs.ÌýThe online tool RegMetrics is a digital platform to support health technology innovators in navigating the medical device regulations. The technology was initially developed by the Natural Interaction Lab () at the University of Oxford, as a solution for a need that was observed within the community of innovators.Ìý

IP (Intellectual property) - UCL resources

UCLB (tech transfer office) follows any development for intellectual property establishment at »Ê¼Ò»ªÈË.

- General policy:ÌýUCL Intellectual Property (IP) Policy | Innovation & Enterprise - UCL – University College London
-ÌýCommercialisation of an IP and revenue sharing policy at »Ê¼Ò»ªÈË:ÌýUCL Revenue Sharing Policy | Innovation & Enterprise - UCL – University College London
-ÌýNon-patentable IP:Ìý

For any enquires see UCB Q&AÌýÌýor contact one of the Business Managers:Ìý,Ìý.Ìý

PPI (Patient and Public involvement)

Evidence of involving patients and the public in the planning, design, management and/or dissemination of research is increasingly a requirement of major funding bodies in the UK. UCLÌýprovideS an online PPI helpdesk that researchers can contact PatienceÌýfor advice on PPI. The helpdesk can be contacted onÌýppihelpdesk@ucl.ac.uk.

Other resources are:

- The JROÌýAbout |ÌýAbout | Joint Research Office - UCL – University College London
- The NIHR UCLH Biomedical Research Centre runs a programme of regular workshops for researchers at »Ê¼Ò»ªÈË Partner organisations on patient and public involvement (PPI) in research.Ìý
-Ìý
- Charities